title: Live attenuated influenza vaccine tetravalent: a clinical review.
abstract: Live attenuated influenza vaccine (LAIV) has been available as a trivalent formulation in the EU since 2012. Influenza B strains from two lineages have co-circulated outside Asia in Europe, Israel and North America since the early 2000s. The trivalent vaccine contained a single influenza B lineage virus chosen primarily on the basis of the previous year's circulating lineage. Failure to align the vaccine virus with the circulating virus leaves even vaccinated patients, particularly children, at risk for infection with B viruses from the other lineage. Recently, a tetravalent formulation was approved and use will begin during the 2014-2015 influenza season. Approval of LAIV Tetra was based on the established efficacy and safety of trivalent LAIV and studies demonstrating similar immunogenicity between the trivalent and tetravalent vaccines. Addition of a fourth strain to the vaccine will address the issue of co-circulation of influenza B viruses and provide a broader range of protection.
authors: AstraZeneca One MedImmune Way, Gaithersburg, MD 20878, USA.
authors: Allyn R
authors: AR
authors: Bandell
authors: Eric A F
authors: EA
authors: Simões
mesh_terms: D017277:Drug Approval; D006801:Humans; D009980:Influenza A virus / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D014481:United States; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
chemical_list: D007252:Influenza Vaccines; D014613:Vaccines, Attenuated
keywords: intranasal influenza vaccine; live attenuated influenza vaccine; tetra; tetravalent